Atea Pharmaceuticals Ownership

AVIR -  USA Stock  

USD 27.13  0.90  3.43%

Some institutional investors establish a significant position in stocks such as Atea Pharmaceuticals in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Atea Pharmaceuticals, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits. Please continue to Trending Equities.

Search Ownership Allocation 

 
Refresh
Atea Pharmaceuticals Long Term Debt to Equity is relatively stable at the moment as compared to the past year. Atea Pharmaceuticals reported last year Long Term Debt to Equity of 0.00615. As of 09/19/2021, Accounts Payable Turnover is likely to grow to 51.90, while Receivables Turnover is likely to drop 13.11.
Atea Pharmaceuticals holds a total of eighty-two million seven hundred fourty thousand outstanding shares. Over half of Atea Pharmaceuticals outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulation than regular investors in Atea Pharmaceuticals. Please watch out for any change in the institutional holdings of Atea Pharmaceuticals as this could mean something significant has changed or about to change at the company. Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.

Atea Pharmaceuticals Stock Ownership Analysis

About 18.0% of the company shares are held by company insiders. The book value of Atea Pharmaceuticals was presently reported as 13.09. The company recorded a loss per share of 0.64. Atea Pharmaceuticals next dividend is scheduled to be issued on the 9th of November 2012. The entity had 1:6 split on the 9th of November 2012. Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts. Atea Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs people. For more info on Atea Pharmaceuticals please contact Joseph Patti at 678 221-3343 or go to www.aviragentherapeutics.com.
Besides selling stocks to institutional investors, Atea Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Atea Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Atea Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Atea Pharmaceuticals Quarterly Share Based Compensation

10.01 MillionShare
About 18.0% of Atea Pharmaceuticals are currently held by insiders. Unlike Atea Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Atea Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%.

Atea Pharmaceuticals SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Atea Pharmaceuticals prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Atea Pharmaceuticals investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Atea Pharmaceuticals specific information freely available to individual and institutional investors to make a timely investment decision.
3rd of September 2021
Unclassified Corporate Event
View
12th of August 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
21st of June 2021
Submission of Matters to a Vote of Security Holders
View

Atea Pharmaceuticals Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Atea Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Atea Pharmaceuticals backward and forwards among themselves. Atea Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Atea Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Fmr LlcCommon Shares12.4 M266.6 M
Cormorant Asset Management LpCommon Shares6.4 M137.7 M
Bain Capital Life Sciences Investors LlcCommon Shares5.6 M120.6 M
Ra Capital Management LpCommon Shares5.4 M115.3 M
Vanguard Group IncCommon Shares4.5 M97.4 M
Blackrock IncCommon Shares3.5 M75 M
Perceptive Advisors LlcCommon Shares2.3 M48.5 M
Note, although Atea Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Atea Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Atea Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Atea Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Atea Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Atea Pharmaceuticals without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run ETF Directory Now

   

ETF Directory

Find actively traded Exchange Traded Funds (ETF) from around the world
All  Next Launch Module

Pair Trading with Atea Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atea Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atea Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Atea Pharmaceuticals Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Atea Pharmaceuticals and Equillium. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Please continue to Trending Equities. Note that the Atea Pharmaceuticals information on this page should be used as a complementary analysis to other Atea Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Complementary Tools for Atea Pharmaceuticals Stock analysis

When running Atea Pharmaceuticals price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
The market value of Atea Pharmaceuticals is measured differently than its book value, which is the value of Atea Pharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Atea Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Atea Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atea Pharmaceuticals' market value can be influenced by many factors that don't directly affect Atea Pharmaceuticals underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atea Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Atea Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atea Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.